RNS Number : 1312J
Proximagen Neuroscience Plc
25 March 2010
|
For immediate release
|
25 March 2010
|
PROXIMAGEN NEUROSCIENCE PLC
("Proximagen" or "the Company")
Notification of Preliminary Results for the twelve months
ended 30 November 2009
London, UK, 25 March 2010 - Proximagen Neuroscience plc (AIM: PRX), the biotechnology company focused on diseases of the central nervous system, will announce its Preliminary Results for the twelve months ended 30 November 2009 on Tuesday 30 March 2010.
An analyst briefing will be held at 9.30 am on Tuesday 30 March 2010 at the offices of Pelham Bell Pottinger, 12 Arthur Street, London, EC4R 9AB. Please advise Dan de Belder at Pelham Bell Pottinger on 020 7861 3800 if you plan to attend.
Enquiries
|
Proximagen Neuroscience plc
|
Phone: +44 (0)20 7848 6938
|
|
Kenneth Mulvany, Chief Executive Officer
|
|
|
James Hunter, Finance Director
|
|
|
|
|
|
Evolution Securities Limited (NOMAD)
|
Phone: +44 (0)20 7071 4300
|
|
Stuart Andrews, Bobbie Hilliam, Tim Redfern
|
|
|
|
|
|
Pelham Bell Pottinger
|
Phone: +44 (0)20 7861 3800
|
|
Charles Cook, Dan de Belder, Zoë Pocock
|
|
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORKMGZFKDNGGZM